User:GLBIV/sandbox

WP:COPYARTICLE, old revision of Revolution Medicines which has been deleted, see User talk:GLBIV

Revolution Medicines is a publicly traded (NASDAQ:RVMD) precision medicine biotechnology company that is focused on developing novel therapies for frontier oncology targets, and is focused on the RAS cancer pathway. Their clinical-stage SHP2 inhibitor, RMC-4630, is currently in Phase 1/2, and is facilitated through a partnership with Sanofi Revolution Medicines showed that SHP2 inhibition is an effective form of treatment in cancers with RAS-GTP dependent oncogenic BRAF and NF1 loss of function. Revolution Medicine's recently announced a Phase 1B combination study of RMC-4630 with Amgen's AMG 510.

The company's current platform leverages bRo5 compounds to target various mutant RAS proteins through inhibition of the RAS(ON) state.